M. Paul Gleeson

Dr. M. Paul Gleeson

Department of Biomedical Engineering, Faculty of Engineering, King Mongkut’s Institute of Technology Ladkrabang, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2008 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
M. Paul GleesonM. Paul Gleeson
M. Paul Gleeson

1 March 2011 in Nature Reviews Drug Discovery
Verified
Journal Article
Closed access
PDF file
M. Paul GleesonM. Paul Gleeson
M. Paul Gleeson
AHAnne Hersey
Anne Hersey
DMDino Montanari
Dino Montanari
JOJohn Overington
John Overington

1 June 2008 in Journal of Molecular Graphics and Modelling
Verified
Journal Article
Closed access
SWShane Weaver
Shane Weaver
M. Paul GleesonM. Paul Gleeson
M. Paul Gleeson

28 January 2020 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
NSNalini Schaduangrat
Nalini Schaduangrat
SLSamuel Lampa
Samuel Lampa
SSSaw Simeon
Saw Simeon
M. Paul GleesonM. Paul Gleeson
M. Paul Gleeson
OSOla Spjuth
Ola Spjuth
CNChanin Nantasenamat
Chanin Nantasenamat
The reproducibility of experiments has been a long standing impediment for further scientific progress. Computational methods have been instrumental in drug discovery efforts owing to its multifaceted utilization for data collection, pre-processing, analysis and inference. This article provides an in-depth coverage on the reproducibility of computational drug discovery. This review explores the following topics: (1) the current state-of-the-art on reproducible research, (2) research documentation (e.g. electronic laboratory notebook, Jupyter notebook, etc.), (3) science of reproducible research (i.e. comparison and contrast with related concepts as replicability, reusability and reliability), (4) model development in computational drug discovery, (5) computational issues on model development and deployment, (6) use case scenarios for streamlining the computational drug discovery protocol. In computational disciplines, it has become common practice to share data and programming codes used for numerical calculations as to not only facilitate reproducibility, but also to foster collaborations (i.e. to drive the project further by introducing new ideas, growing the data, augmenting the code, etc.). It is therefore inevitable that the field of computational drug design would adopt an open approach towards the collection, curation and sharing of data/code.

1 February 2011 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
M. Paul GleesonM. Paul Gleeson
M. Paul Gleeson
AHAnne Hersey
Anne Hersey
SHSupa Hannongbua
Supa Hannongbua
ADME prediction is an extremely challenging area as many of the properties we try to predict are a result of multiple physiological processes. In this review we consider how in-silico predictions of ADME processes can be used to help bias medicinal chemistry into more ideal areas of property space, minimizing the number of compounds needed to be synthesized to obtain the required biochemical/physico-chemical profile. While such models are not sufficiently accurate to act as a replacement for in-vivo or in-vitro methods, in-silico methods nevertheless can help us to understand the underlying physico-chemical dependencies of the different ADME properties, and thus can give us inspiration on how to optimize them. Many global in-silico ADME models (i.e generated on large, diverse datasets) have been reported in the literature. In this paper we selectively review representatives from each distinct class and discuss their relative utility in drug discovery. For each ADME parameter, we limit our discussion to the most recent, most predictive or most insightful examples in the literature to highlight the current state of the art. In each case we briefly summarize the different types of models available for each parameter (i.e simple rules, physico-chemical and 3D based QSAR predictions), their overall accuracy and the underlying SAR. We also discuss the utility of the models as related to lead generation and optimization phases of discovery research.

1 August 2009 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
M. Paul GleesonM. Paul Gleeson
M. Paul Gleeson
GBGianpaolo Bravi
Gianpaolo Bravi
SMSandeep Modi
Sandeep Modi
DLDaniel Lowe
Daniel Lowe